0111 Deals QT
BioCentury & Getty Images


Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Jan 12, 2021 | 2:55 AM GMT

Chi-Med, Inmagene partner on immunological indications
Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial

Read the full 665 word article

How to gain access

Continue reading with a
two-week free trial.